ADVANZ PHARMA Corp. Limited announced changes to its board of directors that are consistent with the company's previously disclosed strategic focus on Western Europe. Effective January 1, 2020, Elmar Schnee, an advisor and observer to the Company's Board since March 2019, assumed the role of nonexecutive Chairman of the Board of ADVANZ PHARMA. Mr. Schnee has more than 30 years of seniorlevel pharmaceutical experience including CEO at Merck Serono, and Managing Director at UCB Pharma. He is currently serving on the board of Jazz Pharmaceuticals, and as the Chairman of Santhera Pharmaceuticals and Calliditas Therapeutics. Mr. Schnee succeeds previous Chairman of the Board, Randy Benson, who oversaw the company's successful recapitalization transaction, which concluded in September 2018, the development of its P.L.A.N. strategy and its acquisition of Salagen® and Panretin® from Eisai in March 2019. The company also announced that Adeel Ahmad, ADVANZ PHARMA's Chief Financial Officer, has been appointed to the Board, effective January 1, 2020, on an interim basis pending the appointment of another independent director to the Board. Mr. Ahmad has more than 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the CFO of ADVANZ PHARMA in June 2018, Mr. Ahmad was CFO of the Company's International segment, and before that, Vice President, Finance and Controller of the company.